Search
RAPT Therapeutics Inc
RAPTAdd to Watchlist
58.020USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.68BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+71.30%
Year to Date
+71.30%
1 Year
+691.54%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
48.90%Turnover Ratio
58.020Prev. Close
0.000Low
0.00Turnover
LossP/E Static
8.03P/B
0.00%Div Yield TTM
-77.05%ROA
57.99052wk High
8.55Volume Ratio
-129.87MNet Profit
22.75MShares
-11.6353EPS TTM
0.50Beta
-85.37%ROE
5.66552wk Low
0.07%Amplitude
100.00%Gross Margin
1.68BMarket Cap
0.08Reward/Risk
6.30%Risk Rate
TradingKey Stock Score of RAPT Therapeutics Inc
Currency: USD Updated: 2026-03-02Key Insights
RAPT Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 174 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 53.89.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
RAPT Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
RAPT Therapeutics Inc Highlights
StrengthsRisks
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -4.99, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.77M shares, increasing 0.67% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 25.18K shares of this stock.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
52.714
Target Price
-9.14%
Upside Space
RAPT Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
RAPT Therapeutics Inc Info
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Ticker SymbolRAPT
CompanyRAPT Therapeutics Inc
CEOWong (Brian)
Websitehttps://rapt.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52343.700
+89.400 (+0.17%)
29687.000
-112.300 (-0.38%)
7478.100
+2.600 (+0.04%)
14749.000
-606.000 (-3.95%)
68706.000
-779.000 (-1.12%)
6304.300
+28.900 (+0.46%)
67.404
-0.564 (-0.83%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4063.590
+32.820 (+0.81%)
FAQs
What is the current price of RAPT Therapeutics Inc (RAPT)?
The current price of RAPT Therapeutics Inc (RAPT) is 58.02.
What is the symbol of RAPT Therapeutics Inc?
The ticker symbol of RAPT Therapeutics Inc is RAPT.
What is the 52-week high of RAPT Therapeutics Inc?
The 52-week high of RAPT Therapeutics Inc is 57.99.
What is the 52-week low of RAPT Therapeutics Inc?
The 52-week low of RAPT Therapeutics Inc is 5.67.
What is the market capitalization of RAPT Therapeutics Inc?
The market capitalization of RAPT Therapeutics Inc is 1.68B.
Is RAPT Therapeutics Inc (RAPT) currently rated as Buy, Hold, or Sell?
According to analysts, RAPT Therapeutics Inc (RAPT) has an overall rating of signal_hold, with a price target of 52.71.
What is the Earnings Per Share (EPS TTM) of RAPT Therapeutics Inc (RAPT)?
The Earnings Per Share (EPS TTM) of RAPT Therapeutics Inc (RAPT) is -25.49.